Eric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.
Eric A. Singer, MD, MA, FACS
Advertisement
Articles by Eric A. Singer, MD, MA, FACS
An expert on non-muscle-invasive bladder cancer discusses how data on Cohort B of KEYNOTE-057 presented at the AUA 2023 meeting might impact treatment strategies.
An overview of the study design, patient populations, and eligibility of the KEYNOTE-057 trial, which studied pembrolizumab in patients with high-risk NMIBC.
Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses the use of Bacillus Calmette-Guerin (BCG) as a first-line therapy for non-muscle-invasive bladder cancer (NMIBC), and reviews subsequent treatment options for patients with high-risk NMIBC who are found to be unresponsive to BCG.
Advertisement
Latest Updated Articles
KEYNOTE-057: Pembrolizumab in Patients With High-Risk NMIBCPublished: May 22nd 2023 | Updated:
- Clinical Implications of Recent KEYNOTE-057 Data
Published: May 29th 2023 | Updated:
- Clinical Pearls and Future of Bladder Cancer Treatment
Published: May 29th 2023 | Updated:
- Treatment Options for Non-Muscle-Invasive Bladder Cancer
Published: May 22nd 2023 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
